FDA gelatin BSE guidance endorsed by advisory cmte.; delay of spine removal urged.
This article was originally published in The Tan Sheet
Executive Summary
FDA BOVINE GELATIN SOURCE GUIDANCE SHOULD ALLOW DELAY IN SPINE REMOVAL from cattle carcasses used in gelatin manufacturing, FDA's Transmissible Spongiform Encephalopathies Advisory Committee recommended at a meeting in Bethesda, Md. April 15-16. Otherwise, the committee endorsed the agency's Oct. 7 guidance on BSE (e.g., "mad cow disease") risk products used in gelatin production ("The Tan Sheet" Oct. 13, 1997, p. 17). The guidance applies to all gelatin-containing products regulated by FDA.